

**Petition for *Inter Partes* Review of USPN 7,932,268**

**Filed on behalf of Coalition for Affordable Drugs VIII, LLC**

By: Dr. Gregory Gonsalves

Reg. No. 43,639

2216 Beacon Lane

Falls Church, Virginia 22043

(571) 419-7252

gonsalves@gonsalveslawfirm.com

UNITED STATES PATENT AND TRADEMARK OFFICE

---

**BEFORE THE PATENT TRIAL AND APPEAL BOARD**

---

COALITION FOR AFFORDABLE DRUGS VIII LLC, Petitioner

v.

TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA,

Patent Owner, based on Electronic Records of PTO

U.S. Patent 7,932,268 to Rader

Filing Date: March 7, 2005

Issue Date: April 26, 2011

TITLE: METHODS FOR TREATING DISORDERS OR DISEASES ASSOCIATED WITH  
HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE MINIMIZING SIDE EFFECTS

---

IPR Trial No. TBD

---

**Petition for *Inter Partes* Review of U.S. Patent No. 7,932,268**

***Mail Stop "PATENT BOARD"***

Patent Trial and Appeal Board

U.S. Patent and Trademark Office

P.O. Box 1450

Alexandria, VA 22313-1450

TABLE OF CONTENTS

I. MANDATORY NOTICES UNDER 37 C.F.R. § 42.8.....1

    A. Real Party-in-Interest (37 C.F.R. § 42.8(B)(1))......1

    B. Related Matters (37 C.F.R. § 42.8(b)(2)).....3

    C. Notice of Lead and Back-Up Counsel (37 C.F.R. § 42.8(b)(3)).....3

    D. Service Information under 37 C.F.R. § 42.8(b)(4).....3

    E. Service on Patent Owner Under 37 C.F.R. §§ 42.106(a) and  
        42.105(a).....3

II. GROUNDS FOR STANDING UNDER 37 C.F.R. § 42.104(A). ....4

III. IDENTIFICATION OF CHALLENGE (37 C.F.R. § 42.104(B)). ....4

IV. INTRODUCTION AND SUMMARY OF ARGUMENT.....5

V. THE ‘268 PATENT PRIORITY DATE IS MARCH 7, 2005; THE  
    ‘915 PROVISIONAL DOES NOT SUPPORT THE ISSUED  
    CLAIMS. ....8

    A. No Support for the Full Scope of the Claimed Dose Ranges. ....8

    B. In Addition, No Support for “the Piperidine N-oxide Thereof”. ....10

VI. SCOPE AND CONTENT OF THE PRIOR ART.....12

    A. Elevated Serum Cholesterol and Lipid Levels Were Recognized  
        Risk Factors For Cardiovascular Disease. ....12

    B. Known Drug Classes and Dosing Regimens Pre-March 2003. ....13

    C. The Content of the MTP Inhibitor Art Pre-March 2004.....15

        1. Pink Sheet 2004 is Prior Art. ....16

        2. Stein’s 2004 Presentation – Published Before March 5,  
            2004 and Again by At Least April 15, 2004 – is Prior  
            Art. ....17

**Petition for *Inter Partes* Review of USPN 7,932,268**

3. The Prior Art Taught Step-Wise Dosing of MTP Inhibitors with Seven Dose Levels, the Rationale, and Expected Efficacy. ....23

VII. U.S. PATENT NO. 7,932,268 AND ITS FILE HISTORY. ....26

A. The ‘268 Patent Repeats Information Already Known to Ordinarily-Skilled Artisans. ....26

B. The ‘268 Patent File History. ....27

C. The European Opposition Proceedings. ....29

VIII. THE LEVEL OF ORDINARY SKILL IN THE ART. ....30

IX. CLAIM CONSTRUCTION STATEMENT (37 C.F.R. § 42.104(B)(3)). ....30

X. EXPLANATION OF GROUNDS FOR UNPATENTABILITY. ....32

A. Ground I: Obviousness Over Pink Sheet 2004 in View of Chang.....33

1. The Claimed Lomitapide Escalating-Dosing Approach was Already Taught for Implipapide. ....34

2. Motivation to Combine Pink Sheet 2004 with Chang. ....40

3. Reasonable Expectation of Success With Lomitapide. ....44

B. Ground II: Obviousness Over Stein 2004 in View of Chang. ....47

1. There Are No Non-Obvious Differences Between the Claims and the Prior Art. ....47

2. Motivation to Combine Stein 2004 with Chang. ....53

3. Reasonable Expectation of Success With Lomitapide. ....55

C. Secondary Considerations Presented During Prosecution Do Not Rebut the *Prima Facie* Case of Unpatentability. ....55

XI. CONCLUSION.....60

Petition for *Inter Partes* Review of USPN 7,932,268

EXHIBIT LIST PURSUANT TO 37 C.F.R. § 42.63(e) AND  
TABLE OF ABBREVIATIONS

Ex. No.	Description
1001	Certified U.S. Patent No. 7,932,268 to Rader.
1002	Declaration of Randall M. Zusman, M.D.
1003	Declaration of Michael Mayersohn, Ph.D.
1004	Affidavit of Christopher Butler, Office Manager, Internet Archive, authenticating Internet Archive URLs (June 16, 2015) (attaching as Ex. A:  <i>PPD News &amp; IR Presentations (2004/04/15)</i> (available at <a href="https://web.archive.org/web/20040415065142/http://ppdi.com/PPD_6_12.htm">https://web.archive.org/web/20040415065142/http://ppdi.com/PPD_6_12.htm</a> )).
1005	Affidavit of Christopher Butler, Office Manager, Internet Archive, authenticating Internet Archive URLs (June 12, 2015) (attaching as Ex. A:  <i>PPD News Releases(2004/02/13)</i> (available at <a href="https://web.archive.org/web/20040213233245/http://www.ppdi.com/PPD_U6.htm?ID=126662">https://web.archive.org/web/20040213233245/http://www.ppdi.com/PPD_U6.htm?ID=126662</a> );  <i>PPD News &amp; IR Presentations(2003/12/12)</i> (available at <a href="https://web.archive.org/web/20031212193444/http://ppdi.com/PPD_6_12.htm">https://web.archive.org/web/20031212193444/http://ppdi.com/PPD_6_12.htm</a> );  <i>PPD News &amp; IR Presentations (2004/06/04)</i> (available at <a href="https://web.archive.org/web/20040604203252/http://www.ppdi.com/PPD_6_12.htm">https://web.archive.org/web/20040604203252/http://www.ppdi.com/PPD_6_12.htm</a> )).
1006	Certified U.S. Provisional Patent Application No. 60/550,915.
1007	U.S. Patent No. 7,932,268 (highlighting dosing information not present in U.S. Provisional Patent Application No. 60/550,915).
1008	U.S. Patent Application No. 10/591,923.
1009	<i>In re Application of: Rader</i> , U.S. Patent Application No. 10/591,923, Response to Oct. 21, 2009 Office Action (Apr. 14, 2010).

**Petition for *Inter Partes* Review of USPN 7,932,268**

1010	<i>In re Application of: Rader</i> , U.S. Patent Application No. 10/591,923, Declaration of William Sasiela, Ph.D. (Apr. 8, 2010).
1011	<i>In re Application of: Rader</i> , U.S. Patent Application No. 10/591,923, Response to July 26, 2010 Office Action (Sept. 13, 2010).
1012	<i>In re Application of: Rader</i> , U.S. Patent Application No. 10/591,923, Notice of Allowance (Jan. 25, 2011).
1013	<i>Bayer/PPD Implitapide Development Follows Zetia Model As Statin Add-On</i> , 66 THE PINK SHEET 17 (Feb. 16, 2004).
1014	Evan Stein, CEO & President, MRL Int'l (Division of PPD), Presentation Given at PPD's Analyst Day, <i>Microsomal Triglyceride [sic] Transfer Protein (MTP) Inhibitor (implitapide) program</i> (Feb. 5, 2004).
1015	George Chang et al., <i>Microsomal triglyceride transfer protein (MTP) inhibitors: Discovery of clinically active inhibitors using high-throughput screening and parallel synthesis paradigms</i> , 5 CURRENT OPINION IN DRUG DISCOVERY & DEV. 562 (2002).
1016	Charles E. Chandler et al., <i>CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans</i> , 44 J. OF LIPID RES. 1887 (2003).
1017	<i>FDA approves Zetia -- first new class to treat cholesterol since statins introduced</i> , DRUGS.COM (Oct. 28, 2002), <a href="http://www.drugs.com/news/fda-approves-zetia-first-new-class-cholesterol-since-statin-introduced-3164.html">http://www.drugs.com/news/fda-approves-zetia-first-new-class-cholesterol-since-statin-introduced-3164.html</a> (last visited July 22, 2015).
1018	John R. Wetterau et al., <i>An MTP Inhibitor That Normalizes Atherogenic Lipoprotein Levels in WHHL Rabbits</i> , 282 SCI. 751 (1998).
1019	U.S. Patent No. 5,712,279 to Biller et al.
1020	Evan Stein, OPPOSITION AGAINST EUROPEAN PATENT NO. 1 725 234 B9 (filed Aug. 21, 2013).

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.